Camurus AB announces that the leading drug dependence journal Addiction has published full results from a 48-week, open-label, global Phase 3 study of weekly and monthly Buvidal® (prolonged-release buprenorphine), the first and only long-acting injection medicine to be approved for the treatment of opioid dependence in the EU and Australia. The study confirmed the safety and efficacy of Buvidal® in both new-to-treatment patients and patients transferring from standard of care with daily sublingual buprenorphine/naloxone. Buvidal®, formulated with Camurus' FluidCrystal® injection depot technology, offers flexible and individualized weekly and monthly dosing, according to patient needs. A total of 227 patients received treatment with Buvidal® in the long-term Phase 3 safety study, which was conducted at 26 sites across the US, UK, Denmark, Sweden, Germany, Hungary and Australia. In total, 167 patients (73.6%) completed the 48-week study, with more than 5,000 injections of Buvidal® administered. Buvidal® was well-tolerated and had a systemic safety profile consistent with the known profile of buprenorphine. In a patient satisfaction survey, 83.4% of participants who were transferred from daily sublingual buprenorphine responded that Buvidal® was "much better" (68.4%) or "slightly better" (15.0%) than their previous treatment. Furthermore, weekly and monthly Buvidal® was effective in reducing and maintaining low opioid withdrawal and cravings scores. The degree of abstinence at the end of the treatment period was high, with 63.0% (17/37) of new-to-treatment patients and 82.8% (111/190) of patients transferred from daily sublingual buprenorphine having negative urine tests (including negative self-reports for illicit opioid use). Importantly, no opioid overdoses were reported for patients treated with Buvidal®.